Incidence of hand-foot syndrome with protein kinase inhibitors in advanced hepatocellular carcinoma patients who received atezolizumab-bevacizumab combination
Journal of Oncology Pharmacy Practice · 2024
DOI: 10.1177/10781552241269738 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Oncology Pharmacy Practice, 2024. Verfasst von Marine Perrier und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Digestive Oncology, Université Reims Champagne-Ardenne, BioSpecT, CHU Reims, Reims, France. Hauptthemen laut MEDLINE: Bevacizumab, Carcinoma, Hepatocellular, Liver Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
Introduction
Treatment of advanced HepatoCellular Carcinoma (HCC) is based on first-line (L1) combination of atezolizumab and high-dose (HD) bevacizumab while second-line (L2) refers one antiangiogenic protein kinase inhibitors (aaPKI). This prolonged antiangiogenic pressure let us to observe an increasing occurrence of Hand-Foot Syndromes (HFS) in patients receiving aaPKI after HD bevacizumab combination. This study reports observations and discussions about the evidence and hypothesis that could be made.
Methods
Patients who received the L1 combination from September 1 st 2020 to December 31 st 2022 to identify L2 aaPKI. Demographic, biological, oncological data and occurrence of HFS were collected. In addition were collected the number of L1 combination cycles, type of aaPKI, and delay between last L1 cycle and L2 initiation. This study had a purely exploratory purpose, so no statistical analysis was planned.
Results
17 patients received an aaPKI after the L1 HD bevacizumab combination with a median time of 26 days from last L1 cycle to L2 start. Five patients experienced HFS including grade 3 ( n = 2) with sorafenib and cabozantinib. The HFS occurred with a median delay of 23 days (IQR: 21–28) from aaPKI start. Three patients experienced aaPKI-related dose-limiting toxicity.
Conclusions
Proportion of patients experienced HFS in our cohort did not differ from pivotal trials data and the sample size do not allow to conclude. Hypotheses include timing of aaPKI start in HCC treatment, vascular toxicity at aaPKI start after HD bevacizumab discontinuation instead combination, patient-related outcome for a better understanding of these aaPKI-related HFS post HD bevacizumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Digestive Oncology, Université Reims Champagne-Ardenne, BioSpecT, CHU Reims, Reims, France.
- Department of Pharmacy, Université Reims Champagne-Ardenne, BioSpecT, CHU Reims, Reims, France.
- Oncology Day-Hospital, CHU Reims, Reims, France.
- Department of Gastroenterology, CH de la Côte Basque, Bayonne, France.
ORCID-Profile: Florian Slimano
Zitieren
APA
Perrier, M., Zuccaro, E., Carlier, C., Brugel, M., Slimano, F., & Bouché, O. (2024). Incidence of hand-foot syndrome with protein kinase inhibitors in advanced hepatocellular carcinoma patients who received atezolizumab-bevacizumab combination. Journal of Oncology Pharmacy Practice. https://doi.org/10.1177/10781552241269738
Vancouver
Perrier M, Zuccaro E, Carlier C, Brugel M, Slimano F, Bouché O. Incidence of hand-foot syndrome with protein kinase inhibitors in advanced hepatocellular carcinoma patients who received atezolizumab-bevacizumab combination. Journal of Oncology Pharmacy Practice. 2024. doi:10.1177/10781552241269738
BibTeX
@article{Perrier2024,
author = {Perrier, Marine and Zuccaro, Emma and Carlier, Claire and Brugel, Mathias and Slimano, Florian and Bouché, Olivier},
title = {Incidence of hand-foot syndrome with protein kinase inhibitors in advanced hepatocellular carcinoma patients who received atezolizumab-bevacizumab combination},
journal = {Journal of Oncology Pharmacy Practice},
year = {2024},
doi = {10.1177/10781552241269738}
}
EUVIMED